Latest Content

The SUCCESSOR-2 study shows MeziKd improves progression-free survival for relapsed multiple myeloma patients previously treated with anti-CD38 drugs.

Dr. Christopher Koller discusses rising kidney cancer diagnoses in younger adults, key risk factors and why early detection remains critical.

A personal look at choosing to be a caregiver, the challenges faced, and the lessons learned while supporting a sister through years with cancer.

Ipsen has pulled Tazverik from all markets after a trial found risks of secondary blood cancers, affecting patients with follicular lymphoma and epithelioid sarcoma.

Dr. Hope Rugo explains how antibody-drug conjugates like Datroway and Trodelvy are shifting the treatment landscape for patients with TNBC.

The FDA has received a new application for Anktiva plus BCG to treat BCG-unresponsive non–muscle invasive bladder cancer with papillary tumors.

FDA grants priority review to Enhertu for patients with HER2-positive early breast cancer and residual invasive disease after neoadjuvant treatment.

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

Zovegalisib plus Faslodex elicited responses in patients with HR-positive, HER2-negative, PIK3CA-mutant advanced breast cancer.

Manage your stage 3 ET diagnosis with this guide on high-risk treatments, side effects and new NCCN-preferred options to empower your next visit.

Here are five key takeaways regarding the use of GLP-1 receptor agonists in patients who are undergoing breast cancer treatment.

At the Miami Breast Cancer Conference, Dr. Heather A. Parsons shared growing evidence for the prognostic value of circulating tumor DNA.